As expected, HAL’s NAV was hit by the market turmoil experienced since the end of February. Although the share prices of HAL’s listed assets drove this decrease, the health crisis impact on the holding company’s unlisted subsidiaries was negligible in Q1. While this will certainly not be the case in Q2, the confirmation that the GrandVision deal remains on schedule should reassure investors about HAL’s long-term prospects.
